CJC-1295 vs Tesamorelin
A long-acting GHRH analog engineered to stretch GH pulses. An FDA-approved GHRH analog that selectively trims visceral fat. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
CJC-1295 | Tesamorelin | |
|---|---|---|
| Also known as | — | Egrifta |
| Type | Analog | Analog |
| Evidence | Limited | Clinical |
| Family | Growth & repair | Growth & repair |
| Class | GHRH(1-29) analog (with or without a drug-affinity complex) | Stabilized GHRH(1-44) analog |
| Receptor | GHRH receptor (GHRHR), a class B GPCR | GHRH receptor (GHRHR), a class B GPCR |
| Molecular weight | ≈3,647 Da | ≈5,136 Da |
| Half-life | ~6-8 days (DAC form); ~30 min without DAC | |
| Based on | Growth-hormone-releasing hormone | Growth-hormone-releasing hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between CJC-1295 and Tesamorelin?
- CJC-1295 is an engineered analog based on Growth-hormone-releasing hormone; Tesamorelin is an engineered analog based on Growth-hormone-releasing hormone. CJC-1295 signals at GHRH receptor (GHRHR), a class B GPCR; Tesamorelin signals at GHRH receptor (GHRHR), a class B GPCR.
- How do the half-lives of CJC-1295 and Tesamorelin compare?
- The reported circulating half-life of CJC-1295 is ~6-8 days (DAC form); ~30 min without DAC; Tesamorelin is ~26-38 min (subcutaneous). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tesamorelin vs CJC-1295. Or open the interactive comparison tool to add more molecules.